BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
Bio-Techne (NASDAQ: TECH) reported its Q4 and full fiscal year 2024 results. Q4 organic revenue increased by 1% (2% reported) to $306.1 million, while full-year organic revenue grew 1% (2% reported) to $1.2 billion. Q4 GAAP EPS was $0.25, down from $0.47 a year ago, and adjusted EPS was $0.49, compared to $0.55 last year. Full-year GAAP EPS decreased to $1.05 from $1.76, and adjusted EPS fell to $1.77 from $1.99. The Diagnostics & Genomics segment showed strong performance with 9% organic growth in Q4 and 6% for the full year. Cash flow from operations increased by 18% to $299.0 million for fiscal 2024. The company noted stabilization in biopharma and China markets, with continued focus on profitability resulting in a 33.5% adjusted operating margin in Q4.
Bio-Techne (NASDAQ: TECH) ha riportato i risultati del quarto trimestre e dell'intero anno fiscale 2024. Le entrate organiche del Q4 sono aumentate dell'1% (2% riportato) a $306,1 milioni, mentre le entrate organiche dell'intero anno sono cresciute dell'1% (2% riportato) a $1,2 miliardi. Il GAAP EPS del Q4 è stato di $0,25, in calo rispetto a $0,47 dell'anno precedente, e l'EPS rettificato è stato di $0,49, rispetto a $0,55 dell'anno scorso. L'EPS GAAP dell'anno intero è diminuito a $1,05 da $1,76, e l'EPS rettificato è sceso a $1,77 da $1,99. Il segmento Diagnostica e Genomica ha mostrato una forte performance con una crescita organica del 9% nel Q4 e del 6% per l'intero anno. Il flusso di cassa dalle operazioni è aumentato del 18% a $299,0 milioni per l'anno fiscale 2024. L'azienda ha notato una stabilizzazione nei mercati biopharma e in Cina, con un continuo focus sulla redditività che ha portato a un margine operativo rettificato del 33,5% nel Q4.
Bio-Techne (NASDAQ: TECH) reportó sus resultados del cuarto trimestre y del año fiscal completo 2024. Los ingresos orgánicos del Q4 aumentaron un 1% (2% reportado) a $306.1 millones, mientras que los ingresos orgánicos del año completo crecieron un 1% (2% reportado) a $1.2 mil millones. El EPS GAAP del Q4 fue de $0.25, en comparación con $0.47 del año anterior, y el EPS ajustado fue de $0.49, en comparación con $0.55 del año pasado. El EPS GAAP para todo el año disminuyó a $1.05 desde $1.76, y el EPS ajustado cayó a $1.77 desde $1.99. El segmento de Diagnósticos y Genómica mostró un sólido rendimiento con un crecimiento orgánico del 9% en el Q4 y del 6% para el año completo. El flujo de caja de las operaciones aumentó un 18% a $299.0 millones para el año fiscal 2024. La compañía notó una estabilización en los mercados de biotecnología y en China, con un enfoque continuo en la rentabilidad que resultó en un margen operativo ajustado del 33.5% en el Q4.
Bio-Techne (NASDAQ: TECH)는 2024 회계연도 4분기 및 전체 연도 실적을 발표했습니다. 4분기 유기 수익은 1% 증가(보고된 수치로는 2%)하여 3억 610만 달러에 달했습니다, 전체 연도 유기 수익은 1% 성장(보고된 수치로는 2%)하여 12억 달러에 이르렀습니다. 4분기 GAAP EPS는 0.25달러로, 작년의 0.47달러에서 감소했으며, 조정 EPS는 0.49달러로, 작년의 0.55달러와 비교됩니다. 전체 연도 GAAP EPS는 1.05달러에서 1.76달러로 감소하였고, 조정 EPS는 1.77달러에서 1.99달러로 떨어졌습니다. 진단 및 유전체 부문은 4분기에 9%의 유기 성장률과 전체 연도에 6%의 성장을 기록하며 강력한 성과를 보였습니다. 2024 회계연도의 운영에서의 현금 흐름은 18% 증가하여 2억 9900만 달러에 달했습니다. 이 회사는 바이오파마 및 중국 시장에서의 안정성과 수익성에 계속 집중하고 있으며, 4분기에는 조정된 운영 마진이 33.5%에 이르렀습니다.
Bio-Techne (NASDAQ: TECH) a annoncé ses résultats pour le quatrième trimestre et l'ensemble de l'exercice fiscal 2024. Le chiffre d'affaires organique du Q4 a augmenté de 1% (2% rapporté) pour atteindre 306,1 millions de dollars, tandis que le chiffre d'affaires organique de l'exercice a augmenté de 1% (2% rapporté) pour s'élever à 1,2 milliard de dollars. Le BPA GAAP du Q4 était de 0,25 dollar, en baisse par rapport à 0,47 dollar l'année précédente, et le BPA ajusté était de 0,49 dollar, comparé à 0,55 dollar l'an dernier. Le BPA GAAP pour l'ensemble de l'année a diminué à 1,05 dollar contre 1,76 dollar, et le BPA ajusté est tombé à 1,77 dollar contre 1,99 dollar. Le segment Diagnostique et Génomique a montré de solides performances avec une croissance organique de 9% au Q4 et de 6% pour l'ensemble de l'année. Le flux de trésorerie provenant des opérations a augmenté de 18% pour atteindre 299,0 millions de dollars pour l'exercice 2024. L'entreprise a noté une stabilisation sur les marchés des biopharmaceutiques et en Chine, avec un accent continu sur la rentabilité, ce qui a permis d'atteindre une marge opérationnelle ajustée de 33,5% au Q4.
Bio-Techne (NASDAQ: TECH) hat seine Ergebnisse für das vierte Quartal und das gesamte Geschäftsjahr 2024 veröffentlicht. Der organische Umsatz im Q4 stieg um 1% (2% berichtigt) auf 306,1 Millionen US-Dollar, während der organische Umsatz im Gesamtjahr um 1% (2% berichtigt) auf 1,2 Milliarden US-Dollar wuchs. Das GAAP EPS im Q4 betrug 0,25 US-Dollar, im Vergleich zu 0,47 US-Dollar im Vorjahr, und das bereinigte EPS betrug 0,49 US-Dollar, verglichen mit 0,55 US-Dollar im letzten Jahr. Das GAAP EPS für das Gesamtjahr sank von 1,76 US-Dollar auf 1,05 US-Dollar, und das bereinigte EPS fiel von 1,99 US-Dollar auf 1,77 US-Dollar. Der Bereich Diagnostik & Genomik zeigte eine starke Leistung mit einem organischen Wachstum von 9% im Q4 und 6% im Gesamtjahr. Der Cashflow aus dem operativen Geschäft stieg um 18% auf 299,0 Millionen US-Dollar im Geschäftsjahr 2024. Das Unternehmen verzeichnete eine Stabilisierung in den Biopharma- und Chinamärkten mit einem anhaltenden Fokus auf Rentabilität, was zu einer bereinigten operativen Marge von 33,5% im Q4 führte.
- Q4 organic revenue increased by 1% to $306.1 million
- Full-year revenue grew to $1.2 billion
- Diagnostics & Genomics segment showed 9% organic growth in Q4
- Cash flow from operations increased by 18% to $299.0 million for fiscal 2024
- 33.5% adjusted operating margin in Q4, representing a 50 basis-point sequential improvement
- Q4 GAAP EPS decreased to $0.25 from $0.47 year-over-year
- Q4 adjusted EPS fell to $0.49 from $0.55 year-over-year
- Full-year GAAP EPS decreased to $1.05 from $1.76
- Full-year adjusted EPS fell to $1.77 from $1.99
- Protein Sciences segment experienced a 4% decrease in Q4 net sales
Insights
Bio-Techne's Q4 FY2024 results show modest growth amidst challenging market conditions. The 1% organic revenue increase to
The 9% organic growth in Diagnostics & Genomics is a bright spot, offsetting the 3% decline in Protein Sciences. The 18% increase in operating cash flow to
The results reflect a stabilizing but still challenging environment in biopharma and China markets. The company's ability to deliver growth, albeit modest, in this context is noteworthy. The strong performance in diagnostics suggests potential market share gains or expanding applications in this sector.
The sequential improvement in adjusted operating margin by 50 basis points indicates effective cost management. However, the year-over-year decline suggests ongoing pressures. The impact of the Lunaphore acquisition on margins highlights the near-term costs of strategic growth initiatives. Investors should monitor how quickly these investments translate into revenue growth and margin expansion in coming quarters.
Bio-Techne's results underscore the current dichotomy in the life sciences tools sector. The strong performance in diagnostics contrasts with softer demand in research-oriented segments, reflecting broader industry trends. The company's focus on growth pillars and core portfolio appears to be providing some insulation against market headwinds.
The decline in Protein Sciences segment is concerning, as it's traditionally been a strong performer. This may indicate broader challenges in academic and biopharma research spending. However, the company's confidence in outperforming as markets normalize suggests potential for accelerated growth when research budgets rebound. The Lunaphore acquisition, while pressuring margins, positions Bio-Techne in the growing spatial biology market, which could be a significant future growth driver.
Fourth Quarter FY2024 Highlights
- Fourth quarter organic revenue increased by
1% (2% reported) to$306.1 million 1% (2% reported) to$1.2 billion - GAAP earnings per share (EPS) was
$0.25 $0.47 $0.49 $0.55 $1.05 $1.76 $1.77 $1.99 - Strong commercial execution in Diagnostics & Genomics led to
9% organic segment growth (15% reported) in the fourth quarter and6% organic segment growth (12% reported) for fiscal year 2024. - Fiscal year 2024 cash flow generated from operations increased to
$299.0 million 18% increase from the prior year.
The Company's financial statements are prepared in accordance with accounting principles generally accepted in
"I am extremely proud of our team's dedication and execution in stabilizing, yet still challenging end-markets." said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We achieved another quarter of solid financial results while experiencing continued stabilization in both our biopharma and
Kelderman added, "Our differentiated financial performance throughout fiscal 2024 showcases the value our growth pillars, as well as our core portfolio, bring to our customers, even when budgets are constrained. This gives us confidence in continued outperformance while life science research end-markets return to historical growth rates."
Bio-Techne will host an earnings conference call today, August 7, 2024 at 8:00 a.m. CDT. To listen, please dial 1-800-343-4136 or 1-203-518-9843 (for international callers), and reference conference ID BioTechne. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11156560. The replay will be available from 11:00 a.m. CDT on Wednesday, August 7, 2024, until 11:00 p.m. CDT on Saturday, September 7, 2024.
Fourth Quarter Fiscal 2024
Revenue
Net sales for the fourth quarter increased
GAAP Earnings Results
GAAP EPS was
Non-GAAP Earnings Results
Adjusted EPS decreased to
Full Year Fiscal 2024
Revenue
Net sales for the full year fiscal 2024 increased
GAAP Earnings Results
GAAP EPS was
Non-GAAP Earnings Results
Adjusted EPS decreased to
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.
Protein Sciences Segment
The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment's fourth quarter fiscal 2024 net sales were
Protein Sciences segment's full year fiscal 2024 net sales were
Diagnostics and Genomics Segment
The Company's Diagnostics and Genomics segment develops and provides spatial biology products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Genomics segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Genomics segment's fourth quarter fiscal 2024 net sales were
The Diagnostics and Genomics segment's full year fiscal 2024 net sales were
Use of non-GAAP Adjusted Financial Measures:
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the
- Organic revenue
- Adjusted diluted earnings per share
- Adjusted net earnings
- Adjusted tax rate
- Adjusted gross margin
- Adjusted operating income
- Adjusted operating margin
- Earnings before interest, taxes, depreciation, and amortization (EBITDA)
- Adjusted EBITDA
We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.
Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal year 2024 due to the sale of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) in the first quarter of fiscal 2023. Revenue from partially-owned consolidated subsidiaries was
Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs, and other non-recurring items including non-recurring costs, goodwill and long-lived asset impairments, and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.
The Company's non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future), certain adjustments to income tax expense, and other non-recurring items including certain costs related to the transition to a new CEO. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.
Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
612-656-4416 |
BIO-TECHNE CORPORATION | ||||||||||||
CONSOLIDATED STATEMENTS OF EARNINGS | ||||||||||||
(In thousands, except per share data) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | YEAR | |||||||||||
ENDED | ENDED | |||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||
Net Sales | $ | 306,098 | $ | 301,320 | $ | 1,159,060 | $ | 1,136,702 | ||||
Cost of sales | 102,751 | 96,623 | 389,335 | 366,887 | ||||||||
Gross margin | 203,347 | 204,697 | 769,725 | 769,815 | ||||||||
Operating Expenses: | ||||||||||||
Selling, general and administrative | 133,536 | 86,754 | 466,375 | 378,378 | ||||||||
Research and development | 23,989 | 23,418 | 96,664 | 92,493 | ||||||||
Total Operating Expenses | 157,525 | 110,172 | 563,039 | 470,871 | ||||||||
Operating income | 45,822 | 94,525 | 206,686 | 298,944 | ||||||||
Other income (expense) | (4,162) | (6,209) | (20,997) | 39,715 | ||||||||
Earnings before income taxes | 41,660 | 88,316 | 185,689 | 338,659 | ||||||||
Income taxes | 1,073 | 12,832 | 17,584 | 53,217 | ||||||||
Net earnings, including noncontrolling interest | $ | 40,587 | $ | 75,484 | $ | 168,105 | $ | 285,442 | ||||
Net earnings attributable to noncontrolling interest | — | — | — | 179 | ||||||||
Net earnings attributable to Bio-Techne | $ | 40,587 | $ | 75,484 | $ | 168,105 | $ | 285,263 | ||||
Earnings per share: | ||||||||||||
Basic | $ | 0.26 | $ | 0.48 | $ | 1.07 | $ | 1.81 | ||||
Diluted | $ | 0.25 | $ | 0.47 | $ | 1.05 | $ | 1.76 | ||||
Weighted average common shares outstanding | ||||||||||||
Basic | 157,868 | 157,504 | 157,708 | 157,179 | ||||||||
Diluted | 160,651 | 161,920 | 160,774 | 161,855 | ||||||||
BIO-TECHNE CORPORATION | ||||||
CONSOLIDATED CONDENSED BALANCE SHEETS | ||||||
(In thousands) | ||||||
(Unaudited) | ||||||
6/30/2024 | 6/30/2023 | |||||
ASSETS | ||||||
Cash and equivalents | $ | 151,791 | $ | 180,571 | ||
Short-term available-for-sale investments | 1,072 | 23,739 | ||||
Accounts receivable, net | 241,394 | 218,468 | ||||
Inventories | 179,731 | 171,638 | ||||
Current assets held-for-sale | 9,773 | — | ||||
Other current assets | 33,658 | 27,066 | ||||
Total current assets | 617,419 | 621,482 | ||||
Property and equipment, net | 251,154 | 226,200 | ||||
Right of use assets | 91,285 | 98,326 | ||||
Goodwill and intangible assets, net | 1,479,744 | 1,407,382 | ||||
Other assets | 264,265 | 285,302 | ||||
Total assets | $ | 2,703,867 | $ | 2,638,692 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Accounts payable and accrued expenses | $ | 112,672 | $ | 77,306 | ||
Contract liabilities | 27,930 | 23,069 | ||||
Income taxes payable | 3,706 | 12,022 | ||||
Contingent consideration payable | — | 3,500 | ||||
Operating lease liabilities - current | 12,920 | 11,199 | ||||
Other current liabilities | 2,151 | 1,413 | ||||
Total current liabilities | 159,379 | 128,509 | ||||
Deferred income taxes | 55,863 | 88,982 | ||||
Long-term debt obligations | 319,000 | 350,000 | ||||
Operating lease liabilities | 87,618 | 93,766 | ||||
Other long-term liabilities | 13,157 | 10,919 | ||||
Stockholders' equity | 2,068,850 | 1,966,516 | ||||
Total liabilities and stockholders' equity | $ | 2,703,867 | $ | 2,638,692 | ||
BIO-TECHNE CORPORATION | ||||||||||||
RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | YEAR | |||||||||||
ENDED | ENDED | |||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||
Gross margin percentage - GAAP | 66.4 | % | 67.9 | % | 66.4 | % | 67.7 | % | ||||
Identified adjustments: | ||||||||||||
Costs recognized upon sale of acquired inventory | 0.1 | % | — | % | 0.1 | % | 0.0 | % | ||||
Amortization of intangibles | 3.9 | % | 3.7 | % | 4.0 | % | 4.0 | % | ||||
Stock compensation expense - COGS | 0.1 | % | 0.0 | % | 0.1 | % | 0.1 | % | ||||
Restructuring and restructuring-related costs | 0.5 | % | — | % | 0.3 | % | — | % | ||||
Impact of partially-owned consolidated subsidiaries1) | — | % | — | % | — | % | (0.1) | % | ||||
Impact of business held-for-sale2) | 0.1 | % | — | % | 0.1 | % | — | % | ||||
Gross margin percentage - Adjusted | 71.1 | % | 71.6 | % | 71.0 | % | 71.7 | % | ||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
2) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the quarter ended June 30, 2024, includes the results for the three-months ended for this business held-for-sale. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION | ||||||||||||
RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | YEAR | |||||||||||
ENDED | ENDED | |||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||
Operating margin percentage - GAAP | 15.0 | % | 31.4 | % | 17.8 | % | 26.3 | % | ||||
Identified adjustments: | ||||||||||||
Costs recognized upon sale of acquired inventory | 0.1 | % | — | % | 0.1 | % | 0.0 | % | ||||
Amortization of intangibles | 6.3 | % | 6.2 | % | 6.8 | % | 6.7 | % | ||||
Acquisition related expenses and other | 1.5 | % | (0.2) | % | 0.6 | % | (0.8) | % | ||||
Certain litigation charges | 1.2 | % | — | % | 0.3 | % | — | % | ||||
Stock-based compensation, inclusive of employer taxes | 2.4 | % | (0.6) | % | 3.5 | % | 3.6 | % | ||||
Restructuring and restructuring-related costs | 1.7 | % | 0.3 | % | 1.1 | % | 0.3 | % | ||||
Impairment of assets held-for-sale | 5.2 | % | — | % | 1.9 | % | — | % | ||||
Impact of partially-owned consolidated subsidiaries1) | — | % | — | % | — | % | 0.0 | % | ||||
Impact of business held-for-sale2) | 0.1 | % | — | % | 0.0 | % | — | % | ||||
Operating margin percentage - Adjusted | 33.5 | % | 37.1 | % | 32.1 | % | 36.1 | % | ||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. As disclosed in our use of Non-GAAP Adjusted Financial Measures, the adjusted operating margin percentages excludes partially-owned consolidated revenue and expense amounts. Due to the sale of this partially-owned consolidated subsidiary in the first fiscal quarter of 2023, there was no impact on operating margin for the quarter and year ended June 30, 2024 and the quarter ended June 30, 2023. The excluded revenue and excluded operating income attributable to partially-owned consolidated subsidiaries had a |
2) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the quarter ended June 30, 2024, includes the results for the three-months ended for this business held-for-sale. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION | ||||||||||||||
NON-GAAP ADJUSTED CONSOLIDATED NET EARNINGS and EARNINGS per SHARE | ||||||||||||||
(In thousands, except per share data) (Unaudited) | ||||||||||||||
QUARTER | YEAR | |||||||||||||
ENDED | ENDED | |||||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||||
Net earnings before taxes - GAAP | $ | 41,660 | $ | 88,316 | $ | 185,689 | $ | 338,659 | ||||||
Identified adjustments attributable to Bio-Techne: | ||||||||||||||
Costs recognized upon sale of acquired inventory | 179 | — | 729 | 400 | ||||||||||
Amortization of intangibles | 19,411 | 18,719 | 78,318 | 76,413 | ||||||||||
Amortization of Wilson Wolf intangible assets and acquired inventory | 3,062 | 2,805 | 15,686 | 2,805 | ||||||||||
Acquisition related expenses and other | 4,955 | (477) | 7,564 | (9,147) | ||||||||||
Certain litigation charges | 3,506 | — | 3,506 | — | ||||||||||
Gain on sale of partially-owned consolidated subsidiaries | — | — | — | (11,682) | ||||||||||
Stock-based compensation, inclusive of employer taxes | 7,466 | (1,662) | 40,277 | 41,217 | ||||||||||
Restructuring and restructuring-related costs | 5,087 | 879 | 12,245 | 3,829 | ||||||||||
Investment (gain) loss and other non-operating | 0 | 682 | (283) | (37,646) | ||||||||||
Impairment of assets held-for-sale | 15,926 | — | 21,963 | — | ||||||||||
Impact of partially-owned consolidated subsidiaries1) | — | — | — | (420) | ||||||||||
Impact of business held-for-sale(2) | (447) | — | (525) | — | ||||||||||
Net earnings before taxes - Adjusted1,2) | $ | 100,805 | $ | 109,262 | $ | 365,169 | $ | 404,428 | ||||||
Non-GAAP tax rate | 22.0 | % | 19.2 | % | 22.0 | % | 20.5 | % | ||||||
Non-GAAP tax expense | $ | 22,239 | $ | 20,962 | $ | 80,420 | $ | 82,948 | ||||||
Non-GAAP adjusted net earnings attributable to Bio-Techne1,2) | $ | 78,566 | $ | 88,300 | $ | 284,749 | $ | 321,480 | ||||||
Earnings per share - diluted - Adjusted1,2) | $ | 0.49 | $ | 0.55 | $ | 1.77 | $ | 1.99 | ||||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
2) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the quarter ended June 30, 2024, includes the results for the three-months ended for this business held-for-sale. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION | ||||||||||||
NON-GAAP adjusted tax rate (In percentages) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | YEAR | |||||||||||
ENDED | ENDED | |||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||
GAAP effective tax rate | 2.6 | % | 14.5 | % | 9.5 | % | 15.7 | % | ||||
Discrete items | 20.0 | 3.0 | 14.0 | 3.4 | ||||||||
Impact of non-taxable net gain | — | — | — | 0.7 | ||||||||
Annual forecast update | 0.9 | 2.3 | — | — | ||||||||
Long-term GAAP tax rate | 23.5 | % | 19.8 | % | 23.5 | % | 19.8 | % | ||||
Rate impact items | ||||||||||||
Stock based compensation | (2.8) | % | 0.5 | % | (2.5) | % | (1.4) | % | ||||
Other | 1.3 | (1.1) | 1.0 | 2.1 | ||||||||
Total rate impact items | (1.5) | % | (0.6) | % | (1.5) | % | 0.7 | % | ||||
Non-GAAP adjusted tax rate | 22.0 | % | 19.2 | % | 22.0 | % | 20.5 | % | ||||
BIO-TECHNE CORPORATION | ||||||||||||
SEGMENT REVENUE | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | YEAR | |||||||||||
ENDED | ENDED | |||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||
Protein Sciences segment revenue | $ | 213,988 | $ | 223,008 | $ | 830,902 | $ | 845,747 | ||||
Diagnostics and Genomics segment revenue | 90,678 | 79,025 | 326,392 | 292,602 | ||||||||
Other revenue1) | 2,060 | — | 4,153 | — | ||||||||
lntersegment revenue | (628) | (713) | (2,387) | (1,647) | ||||||||
Consolidated revenue | $ | 306,098 | $ | 301,320 | $ | 1,159,060 | $ | 1,136,702 | ||||
1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the quarter ended June 30, 2024, includes the results for the three-months ended for this business held-for-sale. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION | ||||||||||||
SEGMENT OPERATING INCOME | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | YEAR | |||||||||||
ENDED | ENDED | |||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | |||||||||
Protein Sciences segment operating income | $ | 91,999 | $ | 99,649 | $ | 354,775 | $ | 373,684 | ||||
Diagnostics and Genomics segment operating income | 11,357 | 14,638 | 24,546 | 43,037 | ||||||||
Segment operating income | 103,356 | 114,287 | 379,321 | 416,721 | ||||||||
Corporate general, selling, and administrative | (1,597) | (2,449) | (9,142) | (6,530) | ||||||||
Adjusted operating income | 101,759 | 111,838 | 370,179 | 410,191 | ||||||||
Cost recognized upon sale of acquired inventory | (179) | — | (729) | (400) | ||||||||
Amortization of intangibles | (19,411) | (18,719) | (78,318) | (76,413) | ||||||||
Acquisition related expenses and other | (4,809) | 623 | (6,980) | 9,965 | ||||||||
Certain litigation charges | (3,506) | — | (3,506) | — | ||||||||
Impact of partially-owned consolidated subsidiaries1) | — | — | — | 647 | ||||||||
Stock-based compensation, inclusive of employer taxes | (7,466) | 1,662 | (40,277) | (41,217) | ||||||||
Restructuring and restructuring-related costs | (5,087) | (879) | (12,245) | (3,829) | ||||||||
Impairment of assets held-for-sale | (15,926) | — | (21,963) | — | ||||||||
Impact of business held-for-sale2) | 447 | — | 525 | — | ||||||||
Operating income | $ | 45,822 | $ | 94,525 | $ | 206,686 | $ | 298,944 | ||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
2) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the quarter ended June 30, 2024, includes the results for the three-months ended for this business held-for-sale. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION | |||||||||||
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA | |||||||||||
(In thousands) | |||||||||||
(Unaudited) | |||||||||||
QUARTER | YEAR | ||||||||||
ENDED | ENDED | ||||||||||
6/30/2024 | 6/30/2023 | 6/30/2024 | 6/30/2023 | ||||||||
Net earnings attributable to Bio-Techne | $ | 40,587 | $ | 75,484 | $ | 168,105 | $ | 285,263 | |||
Net interest expense (income) | 1,605 | 2,668 | 12,413 | 7,805 | |||||||
Depreciation and amortization | 28,057 | 26,923 | 111,711 | 107,238 | |||||||
Income taxes | 1,073 | 12,832 | 17,584 | 53,217 | |||||||
EBITDA attributable to Bio-Techne | 71,322 | 117,907 | 309,813 | 453,523 | |||||||
Costs recognized upon sale of acquired inventory | 179 | — | 729 | 400 | |||||||
Acquisition related expenses and other | 4,955 | (477) | 7,564 | (9,147) | |||||||
Certain litigation charges | 3,506 | — | 3,506 | — | |||||||
Amortization of Wilson Wolf intangible assets and acquired inventory | 3,062 | 2,805 | 15,686 | 2,805 | |||||||
Gain on sale of partially-owned consolidated subsidiaries | — | — | — | (11,682) | |||||||
Stock-based compensation, inclusive of employer taxes | 7,466 | (1,662) | 40,277 | 41,217 | |||||||
Restructuring and restructuring-related costs | 5,087 | 879 | 12,245 | 3,829 | |||||||
Investment (gain) loss and other non-operating | 0 | 682 | (283) | (37,646) | |||||||
Impairment of assets held-for-sale | 15,926 | — | 21,963 | — | |||||||
Impact of business held-for-sale2) | (447) | — | (525) | — | |||||||
Impact of partially-owned consolidated subsidiaries1) | — | — | — | (241) | |||||||
Adjusted EBITDA | $ | 111,056 | $ | 120,134 | $ | 410,975 | $ | 443,058 | |||
1) Net earnings attributable to Bio-Techne excludes non-controlling interest of approximately |
2) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the quarter ended June 30, 2024, includes the results for the three-months ended for this business held-for-sale. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION | ||||||
CONDENSED CASH FLOW | ||||||
(In thousands) | ||||||
(Unaudited) | ||||||
YEAR | ||||||
ENDED | ||||||
6/30/2024 | 6/30/2023 | |||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||
Net earnings | $ | 168,105 | $ | 285,442 | ||
Adjustments to reconcile net earnings to net cash provided by operating activities | ||||||
Depreciation and amortization | 111,711 | 107,238 | ||||
Costs recognized on sale of acquired inventory | 729 | 400 | ||||
Deferred income taxes | (39,447) | (29,567) | ||||
Stock-based compensation expense | 38,042 | 39,230 | ||||
Gain on sale of CCXI investment | — | (37,176) | ||||
Fair value adjustment to available-for-sale investments | (283) | (472) | ||||
Loss on equity method investment | 6,841 | 1,143 | ||||
Asset impairment restructuring | 2,634 | — | ||||
Fair value adjustment to contingent consideration payable | (3,500) | (12,100) | ||||
Gain on sale of Eminence | — | (11,682) | ||||
Impairment of assets held-for-sale | 21,963 | — | ||||
Other operating activities | (7,814) | (88,063) | ||||
Net cash provided by (used in) operating activities | 298,981 | 254,393 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||
Proceeds from sale of available-for-sale investments | 28,083 | 35,236 | ||||
Purchases of available-for-sale investments | (5,526) | (20,500) | ||||
Proceeds from sale of CCXI investment | — | 73,219 | ||||
Additions to property and equipment | (62,877) | (38,244) | ||||
Acquisitions, net of cash acquired | (169,707) | (101,184) | ||||
Distributions from (Investments in) Wilson Wolf | 6,997 | (232,000) | ||||
Proceeds from sale of Eminence | — | 17,824 | ||||
Net cash provided by (used in) investing activities | (203,030) | (265,649) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||
Cash dividends | (50,419) | (50,285) | ||||
Proceeds from stock option exercises | 60,935 | 29,813 | ||||
Long-term debt activity, net | (31,000) | 94,000 | ||||
Re-purchases of common stock | (80,042) | (19,562) | ||||
Taxes paid on RSUs and net share settlements | (21,872) | (28,893) | ||||
Other financing activity | — | (2,457) | ||||
Net cash provided by (used in) financing activities | (122,398) | 22,616 | ||||
Effect of exchange rate changes on cash and cash equivalents | (2,333) | (3,356) | ||||
Net increase (decrease) in cash and cash equivalents | (28,780) | 8,004 | ||||
Cash and cash equivalents at beginning of period | 180,571 | 172,567 | ||||
Cash and cash equivalents at end of period | $ | 151,791 | $ | 180,571 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-fourth-quarter-fiscal-2024-results-302216424.html
SOURCE Bio-Techne Corporation
FAQ
What was Bio-Techne's (TECH) Q4 2024 revenue?
How did Bio-Techne's (TECH) EPS change in Q4 2024?
What was Bio-Techne's (TECH) full-year 2024 revenue?
How did Bio-Techne's (TECH) Diagnostics & Genomics segment perform in Q4 2024?
